降浊清肝汤对原发性高血压合并代谢综合征的临床研究
|
摘要
高血压是冠心病、脑率中的主要危险因素。据近年来发表的前瞻性研究结果显示,人群中缺血性心血管病的发病中33%归因于高血压,30%归因于吸烟,10%归因于高胆固醇,3%归因于糖尿病,24%归因于其他因素。在美国公布的一项大规模的,关于代谢综合征的流行病学研究结果中指出,高血压是代谢综合征众多要素中最主要的“贡献者”之一。UKPDS研究表明,强化控制血糖(糖化血红蛋白7.9%～7.0%)与控制血压(舒张压87～82 mmHg)对代谢综合征预后的影响,结果显示强化血压控制更重要。强化血糖控制的结果仅只是中度减少了微血管终点事件,但继续随访至10年时肾功能、视网膜病变、死亡率仍无显著改善,然而强化控制血压,可使心血管事件的危险和死亡率降低2-4倍,而且在降低微血管事件方面,血压控制效果比血糖控制更显著,强化控制血压有着重要的意义
在MS治疗上目前多采用在生活方式干预基础上,降血压、降血糖、调血脂、控制体质量等综合治疗方法,全面防治MS,降低心脑血管病,但尚未取得满意的效果。
众多研究证据表明,炎症在动脉粥样硬化及其并发症的发生发展过程中起着重要作用,CRP是预测心血管危险最有力的炎症标记物。研究表明高血压代谢综合征患者CRP均有显著增高,故在判定高血压合并代谢综合征治疗效果时CRP变化有重要意义。
综上所述,本试验以原发性高血压合并代谢综合征患者为研究对相,突出控制血压的重要意义,总结本病的主要病机为肝胃湿热证,验证经验方-降浊清肝汤治疗原发性高血压合并代谢综合征患者的有效性及安全性。
研究目的：观察降浊清肝汤治疗原发性高血压合并代谢综合征的临床疗效及安全性。
研究方法：将44例原发性高血压合并代谢综合征(肝胃湿热型)患者随机分为治疗组22例和对照组22例,2组患者均采取生活方式干预情况下,治疗组给予降浊清肝汤服用,对照组给予厄贝沙坦片服用,疗程均为4周。观察治疗前后血压、中医症状积分、H-CRP、GLU、CHO、TG、HDL-C、LDL-C及体重指数、腰臀比的变化来判定临床疗效,检测治疗前后呼吸、心率、CR、BUN、UA、ALT、AST、WBC、RBC、HGB、K+、心电图的变化来判定用药安全性。
研究结果：①血压测定：2组药物均能改善收缩压及舒张压,治疗前后比较有统计学差异(P<0.01),2组病例治疗前后收缩压及舒张压差值比较均无统计学差异(P>0.05)。②降血压疗效：治疗组总有效率为86.36%,对照组总有效率为54.55%,治疗组优于对照组,2组比较有统计学差异(P<0.05)。③临床症状改善情况：治疗组药物能改善头痛头晕头胀、胸胁或胃脘苦满、口苦咽干、烦躁易怒症状,对照组药物能改善头痛头晕头胀、咽干、烦躁易怒症状,治疗前后比较,均有统计学差异(p<0.05)。④总疗效(中医症状积分)：治疗组总有效率为95.45%,对照组总有效率为72.73%,治疗组优于对照组,2组比较有统计学差异(P<0.05)。⑤疗效性指标：2组药物均不能改善H-CRP、GLU、CHO、TG、HDL-C、LDL-C、体重指数、腰臀比,治疗前后比较无统计学差异(P>0.05),2组治疗前后H-CRP、GLU、CHO、TG、HDL-C、LDL-C、体重指数、腰臀比差值比较均无统计学差异(P>0.05)。⑥安全性指标：2组治疗前后CR、BUN、UA、ALT、AST、WBC、RBC、HGB、PLT、呼吸、心率、心电图比较无明显变化。
结论：①降浊清肝汤能改善收缩压及舒张压,且降血压疗效优于厄贝沙坦片②降浊清肝汤能改善头痛头晕头胀、胸胁或胃脘苦满、口苦、咽干、烦躁易怒症状,且中医疗效(中医症状积分)优于厄贝沙坦片。③降浊清肝汤不能改善H-CRP、GLU、CHO、TG、HDL-C、LDL-C、体重指数、腰臀比。④降浊清肝汤具有用药安全性。
Hypertension is the major risk factor of coronary heart disease and stroke.According to recently published prospective study,of the population incidence of ischemic cardiovascular diseases,33% were due to hypertension, 30% were due to smoking tobacco,10% were due to high cholesterol,3% were due to diabetes and 24% attributed to other factors.This year the United States of America announced a large-scale epidemiological studies on the results of metabolic syndrome that hypertension is the most important "contributor"of many elements of metabolic syndrome.Compared with the normal population, high blood pressure in patients with metabolic syndrome is more popular. What kind of treatment modalities should we establish to get better treatment of hypertension and metabolic syndrome,and more effectively reduce cardiovascular risk? UKPDS Studies have shown that enhanced blood pressure control is more important on the prognosis of metabolic syndrome between enhanced control of blood glucose (glycosylated hemoglobin 7.9%-7.0%) and control blood pressure (diastolic blood pressure 87-82 mmHg).The result of intensive glycemic control is only moderately reduced microvascular end point, but continued follow-up to 10 years, renal function, retinopathy, still no significant improvement in mortality, however, strengthening the control of blood pressure, can lower the risk of cardiovascular events and mortality 2 to 4 times, and in reducing microvascular events, the effect of blood pressure control is more pronounced than blood glucose control. Lfestyle intervention is currently more used in the treatment of MS.The comprehensive treatment of blood pressur,blood sugar,lipids and body weight control can prevent and control MS,which can reduce cardiovascular and cerebrovascular disease, but it has not achieved satisfactory results.
Many studies suggest that inflammation plays an important role in the development process of atherosclerosis and its complications.CRP is the most powerful predictor of cardiovascular risk markers of inflammation. Many studies reported that CRP increased significantly in high blood pressure and metabolic syndrome.So it is important that CRP changes when determining treatment effect of hypertension and metabolic syndrome.
In summary, the patients with essential hypertension complicated by metabolic syndrome are recruited for the study of the phase, and we highlight the importance of controlling blood pressure.We distinguish the syndrome of hypertension and metabolic syndrome on the major aspects of the liver yang and liver spleen astagnation as the basis for the liver and stomach damp.We used an experienced formula-Jiangzhuo Qinggan formula to treat this disease and verify its effects.
Aim:To explore the clinical efficacy and safety of Jiangzhuo Qinggan formula in the treatment of essential hypertension with metabolic syndrome
Methods:44 patients with with hypertension and metabolic syndrome (damp-heat in liver and stomach) were randomly divided into treatment group(n=22) and control group(n=22).2 groups patients were taken to lifestyle intervention.The treatment group was given Jiangzhuo Qinggan formula,and the control group was given Irbesartan for a course of 4 weeks.Before and after treatment of blood pressure, changes in traditional Chinese medicine symptom score, H-CRP, GLU, CHO, TG, HDL-C, LDL-C and body mass index, waist-hip ratio and other changes are to determine the clinical efficacy.Before and after treatment of breathing, heart rate, CR, BUN, UA, ALT and AST、WBC RBC、HGB、K+、ECG are to determine drug safety.
Results:①The 2 groups of drugs can improve systolic and diastolic blood pressure before and after treatment(P<0.01). Between the two groups, there is no difference in systolic and diastolic blood pressure after treatment(P> 0.05).②Total effective rate of treatment group in improving blood pressure was 86.36%, and that of control group was 54.55%.There is significant difference between the 2 groups(P<0.05).③The drugs of treatment group can improve the syndromes of headache and dizziness stretching, epigastric pain full, bitter mouth, dry throat, irritability, sticky stool. The drug of control group can improve the syndromes of headache and dizziness stretching，throat and irritability after treatment, statistically significant (p<0.05).After treatment,the syndromes of headache and dizziness stretching, epigastric pain full, mouth pain, irritability, sticky stool were improved. There were significant difference between pretreatment and posttreatment (p<0.05).④Total effective rate of treatment group was 95.45% and total effective rate of control group was 72.73%.There is significant difference between the 2 groups(P<0.05).⑤The drugs of treatment group can't improve H-CRP、TG、LDL-C、HDL-C、CHO、GLU,and there is no difference between pretreatment and posttreatment(P>0.05).The drugs of control group can't improve H-CRP、TG、LDL-C、HDL-C、CHO、GLU,and there is no difference between pretreatment and posttreatment P>0.05).⑥There are no difference between pretreatment and posttreatment in CR,BUN,UA,ALT,AST,WBC、RBC、HGB、PLT、K+、frequency of breath,heart rate and ECG(P>0.05).
Conclusion:①Jiangzhuo Qinggan formula can improve systolic and diastolic blood pressure more significant than Irbesartan tablets.②Jiangzhuo Qinggan formula can improve the syndromes of headache and dizziness stretching, epigastric pain full, bitter mouth, dry throat, irritability, sticky stool.③Jiangzhuo
Qinggan formula can't improve the level of H-CRP, GLU, CHO, TG, HDL-C,LDL-C,mass index and waist-to-hipratio.④Jiangzhuo Qinggan formula is a safe drug in clinic.
在MS治疗上目前多采用在生活方式干预基础上,降血压、降血糖、调血脂、控制体质量等综合治疗方法,全面防治MS,降低心脑血管病,但尚未取得满意的效果。
众多研究证据表明,炎症在动脉粥样硬化及其并发症的发生发展过程中起着重要作用,CRP是预测心血管危险最有力的炎症标记物。研究表明高血压代谢综合征患者CRP均有显著增高,故在判定高血压合并代谢综合征治疗效果时CRP变化有重要意义。
综上所述,本试验以原发性高血压合并代谢综合征患者为研究对相,突出控制血压的重要意义,总结本病的主要病机为肝胃湿热证,验证经验方-降浊清肝汤治疗原发性高血压合并代谢综合征患者的有效性及安全性。
研究目的：观察降浊清肝汤治疗原发性高血压合并代谢综合征的临床疗效及安全性。
研究方法：将44例原发性高血压合并代谢综合征(肝胃湿热型)患者随机分为治疗组22例和对照组22例,2组患者均采取生活方式干预情况下,治疗组给予降浊清肝汤服用,对照组给予厄贝沙坦片服用,疗程均为4周。观察治疗前后血压、中医症状积分、H-CRP、GLU、CHO、TG、HDL-C、LDL-C及体重指数、腰臀比的变化来判定临床疗效,检测治疗前后呼吸、心率、CR、BUN、UA、ALT、AST、WBC、RBC、HGB、K+、心电图的变化来判定用药安全性。
研究结果：①血压测定：2组药物均能改善收缩压及舒张压,治疗前后比较有统计学差异(P<0.01),2组病例治疗前后收缩压及舒张压差值比较均无统计学差异(P>0.05)。②降血压疗效：治疗组总有效率为86.36%,对照组总有效率为54.55%,治疗组优于对照组,2组比较有统计学差异(P<0.05)。③临床症状改善情况：治疗组药物能改善头痛头晕头胀、胸胁或胃脘苦满、口苦咽干、烦躁易怒症状,对照组药物能改善头痛头晕头胀、咽干、烦躁易怒症状,治疗前后比较,均有统计学差异(p<0.05)。④总疗效(中医症状积分)：治疗组总有效率为95.45%,对照组总有效率为72.73%,治疗组优于对照组,2组比较有统计学差异(P<0.05)。⑤疗效性指标：2组药物均不能改善H-CRP、GLU、CHO、TG、HDL-C、LDL-C、体重指数、腰臀比,治疗前后比较无统计学差异(P>0.05),2组治疗前后H-CRP、GLU、CHO、TG、HDL-C、LDL-C、体重指数、腰臀比差值比较均无统计学差异(P>0.05)。⑥安全性指标：2组治疗前后CR、BUN、UA、ALT、AST、WBC、RBC、HGB、PLT、呼吸、心率、心电图比较无明显变化。
结论：①降浊清肝汤能改善收缩压及舒张压,且降血压疗效优于厄贝沙坦片②降浊清肝汤能改善头痛头晕头胀、胸胁或胃脘苦满、口苦、咽干、烦躁易怒症状,且中医疗效(中医症状积分)优于厄贝沙坦片。③降浊清肝汤不能改善H-CRP、GLU、CHO、TG、HDL-C、LDL-C、体重指数、腰臀比。④降浊清肝汤具有用药安全性。
Hypertension is the major risk factor of coronary heart disease and stroke.According to recently published prospective study,of the population incidence of ischemic cardiovascular diseases,33% were due to hypertension, 30% were due to smoking tobacco,10% were due to high cholesterol,3% were due to diabetes and 24% attributed to other factors.This year the United States of America announced a large-scale epidemiological studies on the results of metabolic syndrome that hypertension is the most important "contributor"of many elements of metabolic syndrome.Compared with the normal population, high blood pressure in patients with metabolic syndrome is more popular. What kind of treatment modalities should we establish to get better treatment of hypertension and metabolic syndrome,and more effectively reduce cardiovascular risk? UKPDS Studies have shown that enhanced blood pressure control is more important on the prognosis of metabolic syndrome between enhanced control of blood glucose (glycosylated hemoglobin 7.9%-7.0%) and control blood pressure (diastolic blood pressure 87-82 mmHg).The result of intensive glycemic control is only moderately reduced microvascular end point, but continued follow-up to 10 years, renal function, retinopathy, still no significant improvement in mortality, however, strengthening the control of blood pressure, can lower the risk of cardiovascular events and mortality 2 to 4 times, and in reducing microvascular events, the effect of blood pressure control is more pronounced than blood glucose control. Lfestyle intervention is currently more used in the treatment of MS.The comprehensive treatment of blood pressur,blood sugar,lipids and body weight control can prevent and control MS,which can reduce cardiovascular and cerebrovascular disease, but it has not achieved satisfactory results.
Many studies suggest that inflammation plays an important role in the development process of atherosclerosis and its complications.CRP is the most powerful predictor of cardiovascular risk markers of inflammation. Many studies reported that CRP increased significantly in high blood pressure and metabolic syndrome.So it is important that CRP changes when determining treatment effect of hypertension and metabolic syndrome.
In summary, the patients with essential hypertension complicated by metabolic syndrome are recruited for the study of the phase, and we highlight the importance of controlling blood pressure.We distinguish the syndrome of hypertension and metabolic syndrome on the major aspects of the liver yang and liver spleen astagnation as the basis for the liver and stomach damp.We used an experienced formula-Jiangzhuo Qinggan formula to treat this disease and verify its effects.
Aim:To explore the clinical efficacy and safety of Jiangzhuo Qinggan formula in the treatment of essential hypertension with metabolic syndrome
Methods:44 patients with with hypertension and metabolic syndrome (damp-heat in liver and stomach) were randomly divided into treatment group(n=22) and control group(n=22).2 groups patients were taken to lifestyle intervention.The treatment group was given Jiangzhuo Qinggan formula,and the control group was given Irbesartan for a course of 4 weeks.Before and after treatment of blood pressure, changes in traditional Chinese medicine symptom score, H-CRP, GLU, CHO, TG, HDL-C, LDL-C and body mass index, waist-hip ratio and other changes are to determine the clinical efficacy.Before and after treatment of breathing, heart rate, CR, BUN, UA, ALT and AST、WBC RBC、HGB、K+、ECG are to determine drug safety.
Results:①The 2 groups of drugs can improve systolic and diastolic blood pressure before and after treatment(P<0.01). Between the two groups, there is no difference in systolic and diastolic blood pressure after treatment(P> 0.05).②Total effective rate of treatment group in improving blood pressure was 86.36%, and that of control group was 54.55%.There is significant difference between the 2 groups(P<0.05).③The drugs of treatment group can improve the syndromes of headache and dizziness stretching, epigastric pain full, bitter mouth, dry throat, irritability, sticky stool. The drug of control group can improve the syndromes of headache and dizziness stretching，throat and irritability after treatment, statistically significant (p<0.05).After treatment,the syndromes of headache and dizziness stretching, epigastric pain full, mouth pain, irritability, sticky stool were improved. There were significant difference between pretreatment and posttreatment (p<0.05).④Total effective rate of treatment group was 95.45% and total effective rate of control group was 72.73%.There is significant difference between the 2 groups(P<0.05).⑤The drugs of treatment group can't improve H-CRP、TG、LDL-C、HDL-C、CHO、GLU,and there is no difference between pretreatment and posttreatment(P>0.05).The drugs of control group can't improve H-CRP、TG、LDL-C、HDL-C、CHO、GLU,and there is no difference between pretreatment and posttreatment P>0.05).⑥There are no difference between pretreatment and posttreatment in CR,BUN,UA,ALT,AST,WBC、RBC、HGB、PLT、K+、frequency of breath,heart rate and ECG(P>0.05).
Conclusion:①Jiangzhuo Qinggan formula can improve systolic and diastolic blood pressure more significant than Irbesartan tablets.②Jiangzhuo Qinggan formula can improve the syndromes of headache and dizziness stretching, epigastric pain full, bitter mouth, dry throat, irritability, sticky stool.③Jiangzhuo
Qinggan formula can't improve the level of H-CRP, GLU, CHO, TG, HDL-C,LDL-C,mass index and waist-to-hipratio.④Jiangzhuo Qinggan formula is a safe drug in clinic.
引文
1.步长集团.代谢综合征控制血压重要?还是控制血糖重要?[J]. 中华高血压杂志.2007,15 (5):358.
2.邢倩,李昌臣.代谢综合征与高血压[J].中国医师进修杂志.2006,29(11)：2.
3. Li JJ, Fang CH. C-react ive protein is not noly an inf lam matory maker but also adirect causeofcar diovascular disease. Med-H ypotheses.2004,62： 499-506.
4.陈海云,逢增昌.高血压患病现况和影响因素研究[J].现代预防医学.2008,35(7)：1355-1356.
5.张磊,郭伟星.从“水火既济”谈高血压病的中医病机[J].甘肃中医.2010,23(10)：7.
6.潘善余.从痰瘀辨治高血压病浅析[J].浙江中医杂志.2010,10,45(10)：745.
7.李运伦,李静.原发性高血压与热毒证[J].山东中医杂志.2000,19(4)：195-197.
8.张晓磊,张军平.清热解毒法在原发性高血压病治疗中的应用[J].吉林中医药.2010,1,30(1)：23.
9.付长庚,龙霖梓,谢琛,等.调和阴阳畅达气血治疗高血压病[J].辽宁中医杂志.2010,37(10)：1892.
10.方素清,张艳,礼海,等.75例高血压中医证型分布研究[J].辽宁中医杂志,2009,36(2)：164.
11.张云飞.高血压病中医证型与血脂紊乱的相关性[J]. 中医杂志,2007,48： 627.
12.齐连芬,胡元会,方业明,等.老年高血压中医辨证分型与24小时血压变化水平相关性探讨[J].中国中医药信息杂志.2009,16(1)：27.
13.张文,张杜平.高血压中医证型与颈动脉粥样硬化的相关性研究[J].现代中西医结合杂志.2009,18(9)：973.
14.刘志龙,王严冬,刘培中.高血压中医证型与心血管危险因素相关性研究[J].新中医.2009,41(8)：24.
15.范群丽,刘福明.高血压病动态血压与中医辨证分型相关性研究[J].吉林中医药.2010,10,30(10)：859.
16.郭向华.半夏自术天麻汤加味治疗痰浊中阻型高血压病48例[J].河北中医.2009,31(6)：870.
17.王振东.加味黄精四草汤治疗高血压病35例[J].现代中医药.2006,26(5)：3.
18.郑静峡.清肝滁痰汤治疗高血压58例[J].实用中医内科杂志.2007,2 1 (4)： 49.
19.曲政军.清热降压胶囊治疗青壮年高血压病肝火上炎证的临床研究[J].山西中医学院学报.2009,10(3)：50-51.
20.许滔.健脾柔肝汤治疗高血压102例[J].陕西中医.2005,26(7)：658.
21.汪春,杨雨民,程志清,等.中药平肝益肾涤痰饮改善肥胖性高血压患者血压、体质量和相关生活质量的调查[J].中国临床康.2006,10(43)：24-25.
22.董德保.益气化痰汤治疗高血压病临床疗效观察[J]. 四川中医.2006,24(10)：50.
23.胡小勤,陈利国,曾学文,等.丹参酮ⅡA对高血压病血瘀证患者血清损伤血管内皮细胞形态结构的影响[J].辽宁中医杂志.2010,37(11)：2130.
24.张晓霞,王金库.决明天麻饮治疗肝阳上亢型高血压病80例[J].光明中医.2010,1,25(10)：1837.
25.李波.平肝降压汤治疗肝阳上亢型高血压病23例临床观察[J].新中医.2010,12,42(12)：7.
26.黄学敏,马浩亮,马骁.水蛭猪苓降压丸治疗高血压病及对左心室功能的影响[J].陕西中医.2010,31,(10)：1306.
27.孙静,杨林,栗艳.天麻钩藤饮加减治疗高血压病肝阳上亢型64例[J].中国中医急症.2010,9,19(9)：1591.
28.岳煜.天麻钩藤饮联合依那普利治疗原发性高血压51例临床观察[J].中国临床研究2010,11,23(11)：1028.
29.于爱文,杨新民,孟爱霞.息风通络化瘀汤对高血压病及其心血管危险因素干预作用的临床研究[J]. 中国中医急症.2010,11,19(11)：1833.
30.刘存毅.心脑舒通治疗高血压病眩晕30例疗效观察[J].长春中医药大学学报.2010,10,26(5)：709.
31.施萍,姚黎.珍菊降压片对轻中度高血压病降压疗效的观察[J].中西医结合心脑血管病杂.2010,11,8(11)：1289.
32.程敏. 中西医结合治疗原发性高血压病50例临床观察[J]. 中医药导报.2010,9,16(9)：46.
33.郝秋艳,李艳捧,邵宏敏,等. 自拟舒脉降压汤配合北京降压0号治疗高血压病的临床观察[J]. 中国误诊学杂志.2010,11,10,(33)：8119.
34.汤光,李大魁.现代临床药物学[M].北京：化学工业出版社,2003,418.
35.陈志敏.吲哒帕胺治疗原发高血压140例疗效观察[J].中国中医药现代远程教育.2010,10,8(100)：9.
36.刘高华,韩琚珊,金仁俊.心得安治疗诊所高血压病临床观察[J].临床医学.2010,10,30(10)：28.
37.宋泽军,赵璇,徐海蓉,等. 比索洛尔、氯沙坦联合用药对高血压病患者左室重构和左心室舒张功能的影响[J]. 中国社区医师·医学专业.2010,12 (29)： 16.
38.张海.中青年原发性高血压病治疗148例临床观察[J].实用预防医学.2009,4,16(2)：534.
39.张家书.氨氯地平加二甲双胍治疗肥胖高血压病人临床分析[J].现代医药卫生.2010,26(21)：3218.
40.刘强.氨氯地平联合厄贝沙坦治疗原发性高血压病伴高尿酸血症疗效观察[J]. 医学信息.2010,11,23(11)：1.
41.潘建清,林中.氨氯地平与福新普利联合治疗高血压病疗效观察[J].中国杜区医师·医学专业,2010,12(31)：45.
42.王惠英,盛明生,赵进宽.非洛地平缓释剂联合马来酸依那普利治疗原发性高血压病的疗效观察[J].临床合理用药.2010,11,3(22)：41.
43.李晓玉.尼福达在老年高血压病治疗中的应用[J].中国现代药物应.2010,9,4 (18)：174.
44.贺朝忠,刘文敏,杨苹.尼群地平与美托洛尔联用治疗老年性高血压病92例疗效观察[J].华夏医学.2010,23(5)：492.
45.王艳霞,李波,于晓,等.福辛普利对原发性高血压患者血压水平及肾功能指标的影响[J]. 山东医药.2010,50(39)：72.
46.任廷和.倍他乐克合用治疗高血压病临床观察[J].医学信息.2010,9,23(9)：126-128.
47.郝红芬.厄贝沙坦和氢氯噻嗪治疗老年原发性高血压病的临床观察[J].山西医学教育.2010,1：48.
48.靳重方,厄贝沙坦联合美托洛尔对高血压病左室肥厚及心功能的影响[J]. 中国医刊.2010,45(10)：51.
49.颜永进,张跃明,丁宏胜,等.缬沙坦联合呋塞米治疗老年高血压病53例临床观察[J].交通医学.2010,24(5)：520.
50.王新强.海捷亚治疗老年性高血压病的临床疗效研究[J]. 中国现代医生.2010,10,48(29)：27.
51.于海霞,赵兴胜.高血压治疗进展[J].医学综述.2009,6,(12)：1824.
52.中国高血压病防治指南修订委员会. 中国高虹压病防治指南(2005年修订版)[J].高血压杂志,2005,13(增)：5.
53.王辉,邓咏梅健康教育在高血压病治疗中的作用[J].现代预防医学.2009,36 (3)： 485.
54.杨晓红.高血压病的三级预防[J].中国社区医师·医学专业.2010,12(28)：13.
55. Tillett WS,Fraecis T. Serological reactions In pneumonia with a nonprotein sonatic of The pneumococcus[J]. Jexpmed,1930,52 (4):5612.
56. Shrive AK,Cheetham GM,Holden D,et al. Three dimensional structure of human C-reactive Protein. Nat Struct Biol,1996,3 (4):346.
57. Jabs WJ, Logering BA, Gerke P, et al. Kidney as a second site of human C-reactive protein formation in vivo.Eur J immunology,2003,33 (1):152-161.
58. Khreiss T,Jozsef L,Potempa LA,et al Conformational rearrangem ent in C-reactive protein is required for proinflammatory actions on human endothelial cells [J]. Circulation,2004,109 (16):2016-2022.
59. Schwedler SB, Amann K,Wernicke K, et al Native C-reactive protein increases whereasmodified C-reactive protein reduces atherosclerosis in apolipoprotein E-knockoutmice [J].Circulation,2005,112(8):1016-1023.
60. Ji SR,Wu Y,Potempa LA,et al Effect ofmodified C-reactive protein on complement activation:Apossible complement regulatory role ofmodified or monomeric C-reactive protein in atherosclerotic lesions [J]. Arterioscler Thromb Vasc Biol,2006,26 (4):935-941.
61.高建钢,张彩虹,刘凤华.C-反应蛋白的检测及临床应用研究进展[J].内蒙古医学院学报.2008,30(6)：637.
62.杨永昌,王北宁.C反应蛋白的临床研究进展[J].中国误诊学杂志.2007,7(4)： 693.
63.齐藤宪祜.超敏-CRP(hs-CRP)在临床的新应用[G].第五届中日临床技术研讨会论文汇编.2002,10：30-31.
64.张丽.血清高敏C反应蛋白与心血管病关系的研究进展[J].国际检验医学杂志,2006,27(5).
65.邓微,许均黎,陈群等.老年冠心病患者血清白细胞介素-6和白细胞介素-8水平变化及其临床意义[J].中国心血管杂志.1998,3(5)：323 324.
66. 向小卫等.vWF及hs-CRP与原发性高血压发病的相关关系[J].广东医学,2008,11,29(11)：1875.
67. Woodm an RJ,Watts GF, Puddey B, et al Leukocyte count and vascular function in type2 diabetic subjects with treated hypertension [J]. Atherosclerosis,2002,163(1):175-181.
68.党爱民,刘国仗.高尿酸血症和心血管事件的关系[J]. 中国医学论坛报,2003,9：512.
69. Tamakoshi K,Yatsuya H, Kondo T, et al.The metabolic syndrome is associated with elevated circulting C-reactive protein in healthy reference range.a systemic low-grade inflammatory state [J].2003,27(4): 443-449.
70.高血压病患者血浆hs-C RP及NO变化的临床意义[J]. 山东医药.2007,47(2)：54.
71.向德芬等.紫外线照射充氧自血回输疗法对高血压患者血HS-CRP,TNF-a,ICAM-1水平的干预研究[J].贵州医药.2005,29(2)：131.
72.工曦云等.原发性高血压与抗心磷脂抗体及高敏C一反应蛋白相关性研究[J]. 中国心血管病研究杂志.2006,4(10)：744-745.
73.陈明,胡申江,张健,等.不同危险度的高血压病人血管内皮功能[J].高血压杂志.2006,14(4)：257-260.
74. Piechota M, Banach M, Irzmanski R, et al Plasma Endothelinllevels in septic patients[J]. J Intensive Care Med,2007,22 (4):232-239.
75.田卫东,杨志娜,李安均,等.超敏C反应蛋白及胆红素在高血压病中的临床价值[J].国际检验医学杂志.2010,9,31(9)：1015.
76.张海锋,朱桢燕,姚文明,等.血清高敏C反应蛋白与血压的关系[J].血管病杂志.2010,11,38(11)：993.
77.成威等.阿托伐他汀对高血压肾病蛋白尿及C-反应蛋白和白介素-6的影响[J].高血压杂志.2005,12,13(12)：767.
78.杨永超等.高血压病患者血清Hs-CRP的变化及辛伐他汀的干预作用[J].江西医药.2007,42(1)：30.
79.严山.老年高血压患者阿托伐他汀治疗后血清CRP及内皮舒张功能变化及其临床意义[J].吉林医学.2009,1,30(1)：1.
80.彭璐等.氨氯地平及阿折地平对高血压病患者血浆炎性介质hs-CRP和TIMP-1的影响[J].北京医学.2009,31(8)：461.
81.欧雅莉等.贝尼地平对原发性高血压患者血清hs-CRP和MCP-1的影响[J].中国现代医学杂志.2008,18(21)：3182.
82.王邦宁,张凤祥,宋兵,等.比索洛尔对冠心病患者血浆C反应蛋白的影响[J].中国临床保健杂志.2005,8(2)：97-99.
83.王玲,周颖玲,林曙光.高敏C反应蛋白水平的变化与ACE I／D基因多态性的相关性分析[J].第一军医大学学报.2005,25(6)：691-695.
84.黄婼等.奥美沙坦对高血压患者血清hs-CRI、ICAM-1及s CD40L的影响[J].中国分子心脏病学杂志.2007,7(2)：78.
85.陈善.缬沙坦对老年高血压患者血浆炎症因子hs-CRP、IL-6和TNF-α的影响[J].海峡药学.2008,20(12)：97.
86.赵雁翎等.原发性高血压老年患者服用氯沙坦前后VW F、GM P-140、CRP的变化分析[J].现代医院.2006,6(4)：15.
87.吕艳秋,石刚刚.反义寡核苷酸技术研究进展[J].广东医药.2006,27(8)：1270-1272.
88.向德芬等.紫外线照射充氧自血回输疗法对高血压患者血HS-CRP,TNF-a,ICAM-1水平的干预研究[J].贵州医药,2005,29(2)：131.
89.龚敏,张卫萍,白延.银杏叶制剂对冠心病患者血脂、血小板活化因子及C-反应蛋白的影响[J].陕西中医.2005,26(7)：636-637.
90.陈志群,郭梅煌,马建芳,等.黄芪注射液对冠心病患者C反应蛋白和体液免疫的影响[J].实用中西医结合临床.2001,1：3-4.
91.徐立新等.麝香保心丸治疗老年冠心病合并高血压的疗效及血清NO、CRP、HCY的变化[J].中成药,2004,26(增刊)：9.
92.李艳等.养肝益水颗粒对原发性高血压早期肾损害患者血清NO、hs-CRP的影响[J].安徽中医学院学报,2009,28(2)：30.
93.李浩,赵文明,韩永祥,等.中西医结合方案对老年单纯收缩期高血压患者血管内皮功能及超敏C反应蛋白的影响[J].中国中西医结合杂志,2009,29(2)：115.
94. Claudia HT Tam, Vincent KL Lam, Wing-Yee So, Ronald CW Ma, Juliana CN Chan, Maggie CY Ng. Genome-wide linkage scan for factors of metabolic syndrome in a Chinese population. BMC Genetics,2010,11:14.
95. Kotronen A, Yki-Jarvinen H. Fatty liver:A novel component of the metabolic syndrome. Arterioscler Thromb-Vasc Biol,2008,28:27-38.
96. Chen J,Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med,2004,140:167-174.
97. Watanabe H, Tanabe N, Watanabe T, et al. Metabolic syndrome and risk of development of atrial fibrillation:The Niigata Preventive Medicine Study. Circulation,2008,117:1255-1260.
98. Pillar G, Shehadeh N. Abdominal fat and sleep apnea:The chicken or the egg? Diabetes Care,2008,31:S303-S309.
99. Yeh H, Punjabi NM, Wang N, Pankow JS, Duncan BB, Brancati FL. Vital capacity as a predictor of incident type 2 diabetes. The atherosclerosis risk in communities study. Diabetes Care,2005,28:1472-1479.
100. Prevalence of the metabolic syndrome in populations of Asian origin. Comparison of the IDF definition with the NCEP definition. Diabetes research and clinical practice,2007,76(1):57-67.
101. Thomas GN, Ho SY, Janus ED, Lam KS, HedleyAJ, Lam TH:The US National Cholesterol Education Programme Adult Treatment Panel Ⅲ (NCEP ATPⅢ) prevalence of the metabolic syndrome in a Chinese population. Diabetes research and clinical practice,2005,67(3):251-257.
102.阮晔,李锐,黎衍云,等.上海市成人代谢综合征的流行特征[J].中华内分泌代谢杂志.2010,9,26(9)：740.
103. Cheung BM, Wat NM, Man YB, Tam S, Thomas GN, Leung GM, Cheng CH, Woo J, Janus ED, Lau CP, et al:Development of diabetes in Chinese with the metabolic syndrome:a 6-year prospective study. Diabetes care,2007,30(6):1430-1436.
104. Thomas GN, Schooling CM, McGhee SM, Ho SY, Cheung BM, Wat NM, Janus ED, Lam KS, Lam TH: Metabolic syndrome increases all-cause and vascular mortality: the Hong Kong Cardiovascular Risk Factor Study. Clin Endocrinol (Oxf),2007,66 (5):666-671.
105. Ford ES, Giles WH. A comarison of the prevalence of themetabol ic syndrome using two proposed definitions [J]. Dia2betes Care,2003,26:575-581.
106. Caballero E. Obesity, diabetes, and the metabolic syndrome:new challenges in antipsychotic drug therapy [J].CNS Spectr,2003,8 (11 Suppl 2):19-22.
107. The European Group for the study of Insulin Resistance (EGIR) Frequency of theWHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome [J].Diabetes Metab,2002,2:354.
108. Alexander CM, Landsman PB, Teutsch SM, et al. NCEP defined metabollic syndrome, and prevalence of coronary heart disease among NHANES participants age 50 years and older [J].Diabetes,2003,52:1210.
109.中华医学会糖尿病学分会代谢综合征研究协作组1中华医学会糖尿病学分会关于代谢综合征的建议[J].中华糖尿病杂志.2004,12：156.
110.宋秀霞,纪立农.国际糖尿病联盟代谢综合征的全球共识定义[J].中华糖尿病杂志.2005,13：175.
111.仝小林,段军.代谢综合征的中医认识和治疗[J].中日友好医院学报.2002,16(5-6)：347.
112.王文健.代谢综合征的中西医结合防治[J].中西医结合学报.2004,2(5)：393-395.
113.徐远.中医治疗代谢综合征的思路与方法[J].中医杂志.2003,44(4)：301-302.
114.袁灿宇.三术减肥汤对肥胖大鼠模型的影响[J].中医研究.2004,17(4)：13.
115.张志玲,李惠林,张黎群,等.活血降糖饮治疗代谢综合征30例疗效观察. 中医药临床杂志,2004,16(4)：327-328.
116.李东晓.痰与代谢综合征[J]. 中国中医基础医学杂志,2005,11(2)：144-146.
117.陆智慧,王勇,毛秉环,等.中西医结合治疗胰岛素抵抗综合征34例临床观察.湖北中医杂志,2000,22(2)：18-19.
118. Mcterman CL, Mcterman PG, Harte AL, et al. Resistin, central obes i ty, and type 2 diabetes[J]. Lancet,2002,359 (9300):46-47.
119. Steppen CM,Bailey ST,Bhat S, et al. The hormone resistin links obesity to diabetes [J]. Nature,2001,409(3):307-312.
120. Recasens M, Ricart W, Fernandez-Real JM. Obesity and inflammation [J].Revista DeMedicina De La Universidad De Navarra,2004,48(2):49-54.
121. Yamauchi T, Kamon J,Waki H, et al. The fat2derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obes ity [J]. Nat Med,2001,7(8):941-946.
122. Okamoto Y, Kihara S, Funahashi T,et al.Adiponectin:a key adipocytokine inmetabolic syndrome[J]. Clin Sci (London, England:1979),2006,110 (3):267-278.
123. CohenMM. Role of lep tin in regulating appetite, neuroendocrine function, and bone remodeling[J]. Am J Med GenetA,2006,140 (5): 5152524.
124. Huang KC, L in RC, KormasN, et al. Plasma lep tin is associated with insulin resistance independent of age, bodymass index, fatmass, lip ids, and pubertal development in nondiabetic adolescents [J]. Intern J Obes RelatMetab Disord,2004,28 (4):470-475.
125. Franks PW, B rage S, Luan J, et al. Lep tin p redicts a worsening of the features of the metabolic syndrome independently of obesity[J].Obes Res,2005,13 (8):1476-1484.
126. Lee JH, Reed DR, Price RA. Lep tin resistance is as.sociatedwith extreme obesity and aggregates in families[J]. Intern J Obes RelatMetab Disord,2001,25(10):1471-1473.
127. Vetter R,LombardiAM, Fabiris R. Substrate competition and insulin action in animalmodels [J].Obes RelatMetab Disord,2000,24 (suppl Z):22-24.
128. Boden G. Free fatty acids2the link between obesity and insulin resistance [J].Endocr Pract,2001,7(1):44-51.
129. Volanakis JE.Human C-reactive protein expression structure and function[J].Mol. Immunol,2001,38 (1-3):189-197.
130. Doi Y, Wakugawa Y, Kiyohara Y, et al. Elevated C-reactive protein is a predictor of diabetes in a general Japanese population:the Hisayama study. Diabetes Care,2005,28:2497-2500.
131. Ridker PM, Wilson PWF, Grandy SM. Should C-react ive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation,2004,109:2818-2825.
132.张京春,陈可冀.代谢综合征与中西医结合综合干预[J].中国中西医结合杂志.2004,24(11)：1029-1032.
133.仝小林,张志远.中医对代谢综合征的认识和治疗[J].中医杂志.2002,43(9)： 708-709.
134.段军.中医治疗糖尿病的新思路[J].光明中医.2002,17(102)：12-13.
135.徐京育,陈晶,于忠学,等.槐草降压冲剂治疗代谢紊乱综合征的临床 观察[J].中医药信息.2003,20(4)：43.
136.赵玲瑜.中西医结合治疗代谢综合征48例[J].湖南中医杂志.2005,21(2)：47.
137.陈晓雯,何勇,周鑫,等.复方健胰颗粒对代谢综合征患者超敏C反应蛋白和踝肱指数的影响[J].中成药.2010,11,32(11)：1858.
138.赵学兰,李香玲,张琳琳,等.益气散聚方对代谢综合征患者肱动脉血管内皮功能的影响[J].中成药.2010,9,32(9)：1478.
139. Grundy SM, Cleeman J I, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: An American HeartAssociation/National Heart,Lung, and Blood Institute Scientific Statement [J].Circulation,2005,112:2735-2752.
140.林丽香.代谢综合征[J].国外医学(内分泌学分册).2004,24(4)：261263.
141.中华医学会糖尿病学分会代谢综合征研究协作组.中华医学会糖尿病学分会关于代谢综合征的建议[J].中华糖尿病杂志.2004,12(3)：156-161.
142.程莹,潘长玉.Rimonabant：一种有希望的代谢综合征治疗药物[J].中国药物应用与监测.2007,(3)：47.
143.闻静,华琦,谭静,等.原发性高血压患者代谢综合征发病情况的调查与分析[J].中华老年心脑血管病杂志.2007,9(8)：512.
144.杨丹,陈小泉,项美香.代谢综合征与动脉粥样硬化性心血管病[J].临床心血管病杂志.2009,25(6)：415.
145.陈建华,戴红蕾,方力争..超敏C反应蛋白与代谢综合征的相关性研究[J].中华急诊医学杂志.2008,17(3)：302-305.
146.刘雪玲.钩藤的有效成分及降压的特点[J].菏泽医专学报,1996,8(4)：20.
147.石京山,余俊先,陈修平,等.钩藤总碱、钩藤碱和异钩藤碱的药理作用[J].中国药理学报(英文版).2003,24(2)：972.
148.宋·唐慎微撰.重修政和经史证类备用本草(影印本)·神农本草经[M].北京：人民卫生出版社.1982,155.
149.牛向荣.柴胡药理作用研究概述[J].中国药师.2009,1(9)：1310-1311.
150.邵淑丽,徐兴军,马德滨,等.姜黄对小白鼠实验性高脂血症的预防作用[J]. 中医药学报.2002,30(4)：59.
151.宋·唐慎微撰.重修政和经史证类备用本草(影印本)·神农本草经[M].北京：人民卫生出版社,1982,207.
152. Kim DH, Cho KH,Moon S K, et al.Cytoprotective mechanism of baicalin againstendothel ial cell damage by peroxynitrite[J]. PharmPharmacol. 2005,57(12):1581-1590.
153.益文杰,佟继铭,苏丙凡,等.黄芩茎叶总黄酮对家兔实验性动脉粥样硬化的预防作用[J]. 中草药.2005,9(27)：228-229.
154.王伟,张涛,赵明镜,等.S种中药黄酮对血管平滑肌细胞凋亡的交互作用[J].北京中医药大学学报.2000,23(4)：1821.
155.杨永健,周兴文,张鑫.细胞内钙信号的变化调节血管平滑肌细胞增殖[J].高血压杂志.2005,13(5)：292-295.
156.贡济宇,高文义,李银清,等.茺蔚子降血压活性成分筛选的实验研究[J].长春中医药大学学报,2008,24(2)：142.
157.戴伟,李立,刘海波,等.红曲调节血脂作用的研究[J].上海预防医学杂志.2003,15(8)：374-376.
158.郑健全,郭俊霞,金宗濂.红曲对自发性高血压大鼠降压机制研究[J].食品工业技术.2007,28(3)：207-208.
159. 张向红,程黎晖.大黄的药理作用及临床应用研究进展[J]. 中国药业.2009,21(18)
160.王丽英,张丽珍,鲁刚英.大黄药理作用研究进展[J].时珍国医国药.2000,11(4)：383.
2.邢倩,李昌臣.代谢综合征与高血压[J].中国医师进修杂志.2006,29(11)：2.
3. Li JJ, Fang CH. C-react ive protein is not noly an inf lam matory maker but also adirect causeofcar diovascular disease. Med-H ypotheses.2004,62： 499-506.
4.陈海云,逢增昌.高血压患病现况和影响因素研究[J].现代预防医学.2008,35(7)：1355-1356.
5.张磊,郭伟星.从“水火既济”谈高血压病的中医病机[J].甘肃中医.2010,23(10)：7.
6.潘善余.从痰瘀辨治高血压病浅析[J].浙江中医杂志.2010,10,45(10)：745.
7.李运伦,李静.原发性高血压与热毒证[J].山东中医杂志.2000,19(4)：195-197.
8.张晓磊,张军平.清热解毒法在原发性高血压病治疗中的应用[J].吉林中医药.2010,1,30(1)：23.
9.付长庚,龙霖梓,谢琛,等.调和阴阳畅达气血治疗高血压病[J].辽宁中医杂志.2010,37(10)：1892.
10.方素清,张艳,礼海,等.75例高血压中医证型分布研究[J].辽宁中医杂志,2009,36(2)：164.
11.张云飞.高血压病中医证型与血脂紊乱的相关性[J]. 中医杂志,2007,48： 627.
12.齐连芬,胡元会,方业明,等.老年高血压中医辨证分型与24小时血压变化水平相关性探讨[J].中国中医药信息杂志.2009,16(1)：27.
13.张文,张杜平.高血压中医证型与颈动脉粥样硬化的相关性研究[J].现代中西医结合杂志.2009,18(9)：973.
14.刘志龙,王严冬,刘培中.高血压中医证型与心血管危险因素相关性研究[J].新中医.2009,41(8)：24.
15.范群丽,刘福明.高血压病动态血压与中医辨证分型相关性研究[J].吉林中医药.2010,10,30(10)：859.
16.郭向华.半夏自术天麻汤加味治疗痰浊中阻型高血压病48例[J].河北中医.2009,31(6)：870.
17.王振东.加味黄精四草汤治疗高血压病35例[J].现代中医药.2006,26(5)：3.
18.郑静峡.清肝滁痰汤治疗高血压58例[J].实用中医内科杂志.2007,2 1 (4)： 49.
19.曲政军.清热降压胶囊治疗青壮年高血压病肝火上炎证的临床研究[J].山西中医学院学报.2009,10(3)：50-51.
20.许滔.健脾柔肝汤治疗高血压102例[J].陕西中医.2005,26(7)：658.
21.汪春,杨雨民,程志清,等.中药平肝益肾涤痰饮改善肥胖性高血压患者血压、体质量和相关生活质量的调查[J].中国临床康.2006,10(43)：24-25.
22.董德保.益气化痰汤治疗高血压病临床疗效观察[J]. 四川中医.2006,24(10)：50.
23.胡小勤,陈利国,曾学文,等.丹参酮ⅡA对高血压病血瘀证患者血清损伤血管内皮细胞形态结构的影响[J].辽宁中医杂志.2010,37(11)：2130.
24.张晓霞,王金库.决明天麻饮治疗肝阳上亢型高血压病80例[J].光明中医.2010,1,25(10)：1837.
25.李波.平肝降压汤治疗肝阳上亢型高血压病23例临床观察[J].新中医.2010,12,42(12)：7.
26.黄学敏,马浩亮,马骁.水蛭猪苓降压丸治疗高血压病及对左心室功能的影响[J].陕西中医.2010,31,(10)：1306.
27.孙静,杨林,栗艳.天麻钩藤饮加减治疗高血压病肝阳上亢型64例[J].中国中医急症.2010,9,19(9)：1591.
28.岳煜.天麻钩藤饮联合依那普利治疗原发性高血压51例临床观察[J].中国临床研究2010,11,23(11)：1028.
29.于爱文,杨新民,孟爱霞.息风通络化瘀汤对高血压病及其心血管危险因素干预作用的临床研究[J]. 中国中医急症.2010,11,19(11)：1833.
30.刘存毅.心脑舒通治疗高血压病眩晕30例疗效观察[J].长春中医药大学学报.2010,10,26(5)：709.
31.施萍,姚黎.珍菊降压片对轻中度高血压病降压疗效的观察[J].中西医结合心脑血管病杂.2010,11,8(11)：1289.
32.程敏. 中西医结合治疗原发性高血压病50例临床观察[J]. 中医药导报.2010,9,16(9)：46.
33.郝秋艳,李艳捧,邵宏敏,等. 自拟舒脉降压汤配合北京降压0号治疗高血压病的临床观察[J]. 中国误诊学杂志.2010,11,10,(33)：8119.
34.汤光,李大魁.现代临床药物学[M].北京：化学工业出版社,2003,418.
35.陈志敏.吲哒帕胺治疗原发高血压140例疗效观察[J].中国中医药现代远程教育.2010,10,8(100)：9.
36.刘高华,韩琚珊,金仁俊.心得安治疗诊所高血压病临床观察[J].临床医学.2010,10,30(10)：28.
37.宋泽军,赵璇,徐海蓉,等. 比索洛尔、氯沙坦联合用药对高血压病患者左室重构和左心室舒张功能的影响[J]. 中国社区医师·医学专业.2010,12 (29)： 16.
38.张海.中青年原发性高血压病治疗148例临床观察[J].实用预防医学.2009,4,16(2)：534.
39.张家书.氨氯地平加二甲双胍治疗肥胖高血压病人临床分析[J].现代医药卫生.2010,26(21)：3218.
40.刘强.氨氯地平联合厄贝沙坦治疗原发性高血压病伴高尿酸血症疗效观察[J]. 医学信息.2010,11,23(11)：1.
41.潘建清,林中.氨氯地平与福新普利联合治疗高血压病疗效观察[J].中国杜区医师·医学专业,2010,12(31)：45.
42.王惠英,盛明生,赵进宽.非洛地平缓释剂联合马来酸依那普利治疗原发性高血压病的疗效观察[J].临床合理用药.2010,11,3(22)：41.
43.李晓玉.尼福达在老年高血压病治疗中的应用[J].中国现代药物应.2010,9,4 (18)：174.
44.贺朝忠,刘文敏,杨苹.尼群地平与美托洛尔联用治疗老年性高血压病92例疗效观察[J].华夏医学.2010,23(5)：492.
45.王艳霞,李波,于晓,等.福辛普利对原发性高血压患者血压水平及肾功能指标的影响[J]. 山东医药.2010,50(39)：72.
46.任廷和.倍他乐克合用治疗高血压病临床观察[J].医学信息.2010,9,23(9)：126-128.
47.郝红芬.厄贝沙坦和氢氯噻嗪治疗老年原发性高血压病的临床观察[J].山西医学教育.2010,1：48.
48.靳重方,厄贝沙坦联合美托洛尔对高血压病左室肥厚及心功能的影响[J]. 中国医刊.2010,45(10)：51.
49.颜永进,张跃明,丁宏胜,等.缬沙坦联合呋塞米治疗老年高血压病53例临床观察[J].交通医学.2010,24(5)：520.
50.王新强.海捷亚治疗老年性高血压病的临床疗效研究[J]. 中国现代医生.2010,10,48(29)：27.
51.于海霞,赵兴胜.高血压治疗进展[J].医学综述.2009,6,(12)：1824.
52.中国高血压病防治指南修订委员会. 中国高虹压病防治指南(2005年修订版)[J].高血压杂志,2005,13(增)：5.
53.王辉,邓咏梅健康教育在高血压病治疗中的作用[J].现代预防医学.2009,36 (3)： 485.
54.杨晓红.高血压病的三级预防[J].中国社区医师·医学专业.2010,12(28)：13.
55. Tillett WS,Fraecis T. Serological reactions In pneumonia with a nonprotein sonatic of The pneumococcus[J]. Jexpmed,1930,52 (4):5612.
56. Shrive AK,Cheetham GM,Holden D,et al. Three dimensional structure of human C-reactive Protein. Nat Struct Biol,1996,3 (4):346.
57. Jabs WJ, Logering BA, Gerke P, et al. Kidney as a second site of human C-reactive protein formation in vivo.Eur J immunology,2003,33 (1):152-161.
58. Khreiss T,Jozsef L,Potempa LA,et al Conformational rearrangem ent in C-reactive protein is required for proinflammatory actions on human endothelial cells [J]. Circulation,2004,109 (16):2016-2022.
59. Schwedler SB, Amann K,Wernicke K, et al Native C-reactive protein increases whereasmodified C-reactive protein reduces atherosclerosis in apolipoprotein E-knockoutmice [J].Circulation,2005,112(8):1016-1023.
60. Ji SR,Wu Y,Potempa LA,et al Effect ofmodified C-reactive protein on complement activation:Apossible complement regulatory role ofmodified or monomeric C-reactive protein in atherosclerotic lesions [J]. Arterioscler Thromb Vasc Biol,2006,26 (4):935-941.
61.高建钢,张彩虹,刘凤华.C-反应蛋白的检测及临床应用研究进展[J].内蒙古医学院学报.2008,30(6)：637.
62.杨永昌,王北宁.C反应蛋白的临床研究进展[J].中国误诊学杂志.2007,7(4)： 693.
63.齐藤宪祜.超敏-CRP(hs-CRP)在临床的新应用[G].第五届中日临床技术研讨会论文汇编.2002,10：30-31.
64.张丽.血清高敏C反应蛋白与心血管病关系的研究进展[J].国际检验医学杂志,2006,27(5).
65.邓微,许均黎,陈群等.老年冠心病患者血清白细胞介素-6和白细胞介素-8水平变化及其临床意义[J].中国心血管杂志.1998,3(5)：323 324.
66. 向小卫等.vWF及hs-CRP与原发性高血压发病的相关关系[J].广东医学,2008,11,29(11)：1875.
67. Woodm an RJ,Watts GF, Puddey B, et al Leukocyte count and vascular function in type2 diabetic subjects with treated hypertension [J]. Atherosclerosis,2002,163(1):175-181.
68.党爱民,刘国仗.高尿酸血症和心血管事件的关系[J]. 中国医学论坛报,2003,9：512.
69. Tamakoshi K,Yatsuya H, Kondo T, et al.The metabolic syndrome is associated with elevated circulting C-reactive protein in healthy reference range.a systemic low-grade inflammatory state [J].2003,27(4): 443-449.
70.高血压病患者血浆hs-C RP及NO变化的临床意义[J]. 山东医药.2007,47(2)：54.
71.向德芬等.紫外线照射充氧自血回输疗法对高血压患者血HS-CRP,TNF-a,ICAM-1水平的干预研究[J].贵州医药.2005,29(2)：131.
72.工曦云等.原发性高血压与抗心磷脂抗体及高敏C一反应蛋白相关性研究[J]. 中国心血管病研究杂志.2006,4(10)：744-745.
73.陈明,胡申江,张健,等.不同危险度的高血压病人血管内皮功能[J].高血压杂志.2006,14(4)：257-260.
74. Piechota M, Banach M, Irzmanski R, et al Plasma Endothelinllevels in septic patients[J]. J Intensive Care Med,2007,22 (4):232-239.
75.田卫东,杨志娜,李安均,等.超敏C反应蛋白及胆红素在高血压病中的临床价值[J].国际检验医学杂志.2010,9,31(9)：1015.
76.张海锋,朱桢燕,姚文明,等.血清高敏C反应蛋白与血压的关系[J].血管病杂志.2010,11,38(11)：993.
77.成威等.阿托伐他汀对高血压肾病蛋白尿及C-反应蛋白和白介素-6的影响[J].高血压杂志.2005,12,13(12)：767.
78.杨永超等.高血压病患者血清Hs-CRP的变化及辛伐他汀的干预作用[J].江西医药.2007,42(1)：30.
79.严山.老年高血压患者阿托伐他汀治疗后血清CRP及内皮舒张功能变化及其临床意义[J].吉林医学.2009,1,30(1)：1.
80.彭璐等.氨氯地平及阿折地平对高血压病患者血浆炎性介质hs-CRP和TIMP-1的影响[J].北京医学.2009,31(8)：461.
81.欧雅莉等.贝尼地平对原发性高血压患者血清hs-CRP和MCP-1的影响[J].中国现代医学杂志.2008,18(21)：3182.
82.王邦宁,张凤祥,宋兵,等.比索洛尔对冠心病患者血浆C反应蛋白的影响[J].中国临床保健杂志.2005,8(2)：97-99.
83.王玲,周颖玲,林曙光.高敏C反应蛋白水平的变化与ACE I／D基因多态性的相关性分析[J].第一军医大学学报.2005,25(6)：691-695.
84.黄婼等.奥美沙坦对高血压患者血清hs-CRI、ICAM-1及s CD40L的影响[J].中国分子心脏病学杂志.2007,7(2)：78.
85.陈善.缬沙坦对老年高血压患者血浆炎症因子hs-CRP、IL-6和TNF-α的影响[J].海峡药学.2008,20(12)：97.
86.赵雁翎等.原发性高血压老年患者服用氯沙坦前后VW F、GM P-140、CRP的变化分析[J].现代医院.2006,6(4)：15.
87.吕艳秋,石刚刚.反义寡核苷酸技术研究进展[J].广东医药.2006,27(8)：1270-1272.
88.向德芬等.紫外线照射充氧自血回输疗法对高血压患者血HS-CRP,TNF-a,ICAM-1水平的干预研究[J].贵州医药,2005,29(2)：131.
89.龚敏,张卫萍,白延.银杏叶制剂对冠心病患者血脂、血小板活化因子及C-反应蛋白的影响[J].陕西中医.2005,26(7)：636-637.
90.陈志群,郭梅煌,马建芳,等.黄芪注射液对冠心病患者C反应蛋白和体液免疫的影响[J].实用中西医结合临床.2001,1：3-4.
91.徐立新等.麝香保心丸治疗老年冠心病合并高血压的疗效及血清NO、CRP、HCY的变化[J].中成药,2004,26(增刊)：9.
92.李艳等.养肝益水颗粒对原发性高血压早期肾损害患者血清NO、hs-CRP的影响[J].安徽中医学院学报,2009,28(2)：30.
93.李浩,赵文明,韩永祥,等.中西医结合方案对老年单纯收缩期高血压患者血管内皮功能及超敏C反应蛋白的影响[J].中国中西医结合杂志,2009,29(2)：115.
94. Claudia HT Tam, Vincent KL Lam, Wing-Yee So, Ronald CW Ma, Juliana CN Chan, Maggie CY Ng. Genome-wide linkage scan for factors of metabolic syndrome in a Chinese population. BMC Genetics,2010,11:14.
95. Kotronen A, Yki-Jarvinen H. Fatty liver:A novel component of the metabolic syndrome. Arterioscler Thromb-Vasc Biol,2008,28:27-38.
96. Chen J,Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med,2004,140:167-174.
97. Watanabe H, Tanabe N, Watanabe T, et al. Metabolic syndrome and risk of development of atrial fibrillation:The Niigata Preventive Medicine Study. Circulation,2008,117:1255-1260.
98. Pillar G, Shehadeh N. Abdominal fat and sleep apnea:The chicken or the egg? Diabetes Care,2008,31:S303-S309.
99. Yeh H, Punjabi NM, Wang N, Pankow JS, Duncan BB, Brancati FL. Vital capacity as a predictor of incident type 2 diabetes. The atherosclerosis risk in communities study. Diabetes Care,2005,28:1472-1479.
100. Prevalence of the metabolic syndrome in populations of Asian origin. Comparison of the IDF definition with the NCEP definition. Diabetes research and clinical practice,2007,76(1):57-67.
101. Thomas GN, Ho SY, Janus ED, Lam KS, HedleyAJ, Lam TH:The US National Cholesterol Education Programme Adult Treatment Panel Ⅲ (NCEP ATPⅢ) prevalence of the metabolic syndrome in a Chinese population. Diabetes research and clinical practice,2005,67(3):251-257.
102.阮晔,李锐,黎衍云,等.上海市成人代谢综合征的流行特征[J].中华内分泌代谢杂志.2010,9,26(9)：740.
103. Cheung BM, Wat NM, Man YB, Tam S, Thomas GN, Leung GM, Cheng CH, Woo J, Janus ED, Lau CP, et al:Development of diabetes in Chinese with the metabolic syndrome:a 6-year prospective study. Diabetes care,2007,30(6):1430-1436.
104. Thomas GN, Schooling CM, McGhee SM, Ho SY, Cheung BM, Wat NM, Janus ED, Lam KS, Lam TH: Metabolic syndrome increases all-cause and vascular mortality: the Hong Kong Cardiovascular Risk Factor Study. Clin Endocrinol (Oxf),2007,66 (5):666-671.
105. Ford ES, Giles WH. A comarison of the prevalence of themetabol ic syndrome using two proposed definitions [J]. Dia2betes Care,2003,26:575-581.
106. Caballero E. Obesity, diabetes, and the metabolic syndrome:new challenges in antipsychotic drug therapy [J].CNS Spectr,2003,8 (11 Suppl 2):19-22.
107. The European Group for the study of Insulin Resistance (EGIR) Frequency of theWHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome [J].Diabetes Metab,2002,2:354.
108. Alexander CM, Landsman PB, Teutsch SM, et al. NCEP defined metabollic syndrome, and prevalence of coronary heart disease among NHANES participants age 50 years and older [J].Diabetes,2003,52:1210.
109.中华医学会糖尿病学分会代谢综合征研究协作组1中华医学会糖尿病学分会关于代谢综合征的建议[J].中华糖尿病杂志.2004,12：156.
110.宋秀霞,纪立农.国际糖尿病联盟代谢综合征的全球共识定义[J].中华糖尿病杂志.2005,13：175.
111.仝小林,段军.代谢综合征的中医认识和治疗[J].中日友好医院学报.2002,16(5-6)：347.
112.王文健.代谢综合征的中西医结合防治[J].中西医结合学报.2004,2(5)：393-395.
113.徐远.中医治疗代谢综合征的思路与方法[J].中医杂志.2003,44(4)：301-302.
114.袁灿宇.三术减肥汤对肥胖大鼠模型的影响[J].中医研究.2004,17(4)：13.
115.张志玲,李惠林,张黎群,等.活血降糖饮治疗代谢综合征30例疗效观察. 中医药临床杂志,2004,16(4)：327-328.
116.李东晓.痰与代谢综合征[J]. 中国中医基础医学杂志,2005,11(2)：144-146.
117.陆智慧,王勇,毛秉环,等.中西医结合治疗胰岛素抵抗综合征34例临床观察.湖北中医杂志,2000,22(2)：18-19.
118. Mcterman CL, Mcterman PG, Harte AL, et al. Resistin, central obes i ty, and type 2 diabetes[J]. Lancet,2002,359 (9300):46-47.
119. Steppen CM,Bailey ST,Bhat S, et al. The hormone resistin links obesity to diabetes [J]. Nature,2001,409(3):307-312.
120. Recasens M, Ricart W, Fernandez-Real JM. Obesity and inflammation [J].Revista DeMedicina De La Universidad De Navarra,2004,48(2):49-54.
121. Yamauchi T, Kamon J,Waki H, et al. The fat2derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obes ity [J]. Nat Med,2001,7(8):941-946.
122. Okamoto Y, Kihara S, Funahashi T,et al.Adiponectin:a key adipocytokine inmetabolic syndrome[J]. Clin Sci (London, England:1979),2006,110 (3):267-278.
123. CohenMM. Role of lep tin in regulating appetite, neuroendocrine function, and bone remodeling[J]. Am J Med GenetA,2006,140 (5): 5152524.
124. Huang KC, L in RC, KormasN, et al. Plasma lep tin is associated with insulin resistance independent of age, bodymass index, fatmass, lip ids, and pubertal development in nondiabetic adolescents [J]. Intern J Obes RelatMetab Disord,2004,28 (4):470-475.
125. Franks PW, B rage S, Luan J, et al. Lep tin p redicts a worsening of the features of the metabolic syndrome independently of obesity[J].Obes Res,2005,13 (8):1476-1484.
126. Lee JH, Reed DR, Price RA. Lep tin resistance is as.sociatedwith extreme obesity and aggregates in families[J]. Intern J Obes RelatMetab Disord,2001,25(10):1471-1473.
127. Vetter R,LombardiAM, Fabiris R. Substrate competition and insulin action in animalmodels [J].Obes RelatMetab Disord,2000,24 (suppl Z):22-24.
128. Boden G. Free fatty acids2the link between obesity and insulin resistance [J].Endocr Pract,2001,7(1):44-51.
129. Volanakis JE.Human C-reactive protein expression structure and function[J].Mol. Immunol,2001,38 (1-3):189-197.
130. Doi Y, Wakugawa Y, Kiyohara Y, et al. Elevated C-reactive protein is a predictor of diabetes in a general Japanese population:the Hisayama study. Diabetes Care,2005,28:2497-2500.
131. Ridker PM, Wilson PWF, Grandy SM. Should C-react ive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation,2004,109:2818-2825.
132.张京春,陈可冀.代谢综合征与中西医结合综合干预[J].中国中西医结合杂志.2004,24(11)：1029-1032.
133.仝小林,张志远.中医对代谢综合征的认识和治疗[J].中医杂志.2002,43(9)： 708-709.
134.段军.中医治疗糖尿病的新思路[J].光明中医.2002,17(102)：12-13.
135.徐京育,陈晶,于忠学,等.槐草降压冲剂治疗代谢紊乱综合征的临床 观察[J].中医药信息.2003,20(4)：43.
136.赵玲瑜.中西医结合治疗代谢综合征48例[J].湖南中医杂志.2005,21(2)：47.
137.陈晓雯,何勇,周鑫,等.复方健胰颗粒对代谢综合征患者超敏C反应蛋白和踝肱指数的影响[J].中成药.2010,11,32(11)：1858.
138.赵学兰,李香玲,张琳琳,等.益气散聚方对代谢综合征患者肱动脉血管内皮功能的影响[J].中成药.2010,9,32(9)：1478.
139. Grundy SM, Cleeman J I, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: An American HeartAssociation/National Heart,Lung, and Blood Institute Scientific Statement [J].Circulation,2005,112:2735-2752.
140.林丽香.代谢综合征[J].国外医学(内分泌学分册).2004,24(4)：261263.
141.中华医学会糖尿病学分会代谢综合征研究协作组.中华医学会糖尿病学分会关于代谢综合征的建议[J].中华糖尿病杂志.2004,12(3)：156-161.
142.程莹,潘长玉.Rimonabant：一种有希望的代谢综合征治疗药物[J].中国药物应用与监测.2007,(3)：47.
143.闻静,华琦,谭静,等.原发性高血压患者代谢综合征发病情况的调查与分析[J].中华老年心脑血管病杂志.2007,9(8)：512.
144.杨丹,陈小泉,项美香.代谢综合征与动脉粥样硬化性心血管病[J].临床心血管病杂志.2009,25(6)：415.
145.陈建华,戴红蕾,方力争..超敏C反应蛋白与代谢综合征的相关性研究[J].中华急诊医学杂志.2008,17(3)：302-305.
146.刘雪玲.钩藤的有效成分及降压的特点[J].菏泽医专学报,1996,8(4)：20.
147.石京山,余俊先,陈修平,等.钩藤总碱、钩藤碱和异钩藤碱的药理作用[J].中国药理学报(英文版).2003,24(2)：972.
148.宋·唐慎微撰.重修政和经史证类备用本草(影印本)·神农本草经[M].北京：人民卫生出版社.1982,155.
149.牛向荣.柴胡药理作用研究概述[J].中国药师.2009,1(9)：1310-1311.
150.邵淑丽,徐兴军,马德滨,等.姜黄对小白鼠实验性高脂血症的预防作用[J]. 中医药学报.2002,30(4)：59.
151.宋·唐慎微撰.重修政和经史证类备用本草(影印本)·神农本草经[M].北京：人民卫生出版社,1982,207.
152. Kim DH, Cho KH,Moon S K, et al.Cytoprotective mechanism of baicalin againstendothel ial cell damage by peroxynitrite[J]. PharmPharmacol. 2005,57(12):1581-1590.
153.益文杰,佟继铭,苏丙凡,等.黄芩茎叶总黄酮对家兔实验性动脉粥样硬化的预防作用[J]. 中草药.2005,9(27)：228-229.
154.王伟,张涛,赵明镜,等.S种中药黄酮对血管平滑肌细胞凋亡的交互作用[J].北京中医药大学学报.2000,23(4)：1821.
155.杨永健,周兴文,张鑫.细胞内钙信号的变化调节血管平滑肌细胞增殖[J].高血压杂志.2005,13(5)：292-295.
156.贡济宇,高文义,李银清,等.茺蔚子降血压活性成分筛选的实验研究[J].长春中医药大学学报,2008,24(2)：142.
157.戴伟,李立,刘海波,等.红曲调节血脂作用的研究[J].上海预防医学杂志.2003,15(8)：374-376.
158.郑健全,郭俊霞,金宗濂.红曲对自发性高血压大鼠降压机制研究[J].食品工业技术.2007,28(3)：207-208.
159. 张向红,程黎晖.大黄的药理作用及临床应用研究进展[J]. 中国药业.2009,21(18)
160.王丽英,张丽珍,鲁刚英.大黄药理作用研究进展[J].时珍国医国药.2000,11(4)：383.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |